Healthcare / Medical DevicesKOSDAQ
$7650.00
-370.00 (-4.61%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $22.8B · quality 74.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$678.8B
P/E
19.5x
↓EV/EBITDA
13.1x
↑ROE
22.4%
↑Gross Margin
67.5%
↑Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+24.4%
FCF CAGR
+51.9%
FCF margin
31.8%
FCF / Net income
1.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $156.84B · net income $35.22B · FCF $49.82B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $156.84B | $156.84B | $115.25B | $115.63B | $81.51B |
| Net Income | $35.22B | $35.22B | $29.11B | $38.83B | $13.40B |
| EBITDA | $51.47B | $51.47B | $43.34B | $50.31B | $19.88B |
| EPS | 393.00 | 393.00 | 327.00 | 441.00 | 158.00 |
| Gross Margin | 67.5% | 67.5% | 64.3% | 64.2% | 59.9% |
| Operating Margin | 33.0% | 33.0% | 30.2% | 39.8% | 32.8% |
| Net Margin | 22.5% | 22.5% | 25.3% | 33.6% | 16.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.17 | 0.18 | 0.09 |
| Current Ratio | 3.05 | 3.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $49.82B | $49.82B | $12.96B | $22.78B | $14.21B |
| Returns | |||||
| ROE | 22.4% | 22.4% | 23.0% | 39.1% | 23.5% |
| Valuation | |||||
| P/E | 19.47 | 19.47 | 16.30 | 21.20 | 26.14 |
| EV/EBITDA | 13.07 | 13.07 | 10.68 | 16.47 | 18.22 |
| P/B | 4.36 | 4.36 | 3.74 | 8.29 | 6.36 |
| Growth & Yield | |||||
| Revenue Growth | 36.1% | 36.1% | -0.3% | 41.9% | — |
| EPS Growth | 20.2% | 20.2% | -25.9% | 179.1% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
20.0%
EPS terminal req.
$678.81
Spread vs growth
0.2%
5Y implied EPS CAGR
15.9%
EPS terminal req.
$821.36
Spread vs growth
4.3%
10Y implied EPS CAGR
12.9%
EPS terminal req.
$1322.81
Spread vs growth
7.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.7%
Start / end P/E
28.0x → 19.5x
EPS bridge
327.00 → 393.00
Residual
-6.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.